In this issue:
Importance of gut microbiome and clinical responses
Efficacy of brexucabtagene in R/R MCL patients
Use of subcutaneous epcoritamab in highly refractory patients
Development of clinical prediction model for cHL
Evaluation on azacitidine plus CHOP
Addition of pembrolizumab to ICE chemotherapy
Safety, tolerability and antileukemic activity of asciminib monotherapy
ICI delivery to improve chemotherapy
DHITsig to identify molecular heterogeneity of DLBCL
Outcomes in ZUMA-1 in LBCL patients
Please login below to download this issue (PDF)